TNF-related apoptosis-inducing ligand (TRAIL) is a typical member of the tumor necrosis factor (TNF) ligand family that is expressed as a type II membrane protein (memTRAIL) and signals apoptosis via the death domain-containing receptors TRAIL-R1 and -2. Soluble recombinant derivatives of TRAIL (sTRAIL) are considered as novel tumors therapeutics because of their selective apoptosis inducing activity in a variety of human tumors but not in normal cells. Using antagonistic antigen-binding fragment (Fab) preparations of TRAIL-R1-and TRAIL-R2-speci®c antibodies, we demonstrate in this study that TRAIL-R1 becomes activated by both the soluble and the membrane-bound form of the ligand, whereas TRAIL-R2 becomes only activated by mem-TRAIL or soluble TRAIL secondarily cross-linked by antibodies. Furthermore, we show that the restricted signal capacity of sTRAIL can be readily converted into a fully signal competent memTRAIL-like molecule, i.e. a TRAIL-R2 stimulating ligand, by genetic fusion to an antibody derivative that allows antigen-dependent`immobilization' of the fusion protein to cell surfaces. We conclude that antibody targeting-dependent activation can be used to design selective therapeutics derived of those ligands of the TNF family that are biologically inactive in their soluble form. Oncogene (2001) 20, 4101 ± 4106.
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Keywords: antibody-mediated; targeting; apoptosis; tumor; TNF ligand family TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) ligand family that induces apoptosis in a variety of tumor cells, but rarely in normal cells, via stimulation of the death domain-containing receptors TRAIL-R1 and -2 Walczak and Krammer, 2000) . Like other members of the TNF ligand family TRAIL is primarily expressed as a type II membrane protein, but a soluble form derived thereof has also been described (Mariani and Krammer, 1998a) . We have recently found that soluble TRAIL (sTRAIL) induces apoptosis in cell lines that can be killed by agonistic TRAIL-R1-speci®c IgG preparations, whereas secondary cross-linking of sTRAIL was required for induction of apoptosis in cell lines that responded to an agonistic TRAIL-R2-lgG preparation, but not to an agonistic TRAIL-R1-lgG preparation (MuÈ hlenbeck et al., 2000) . These data suggested that TRAIL-R1 equally responds to cross-linked and noncross-linked sTRAIL, whereas TRAIL-R2 signals only in response to cross-linked TRAIL. To obtain ®nal proof of this hypothesis, we prepared monovalent Fabs from TRAIL-R1-and TRAIL-R2-speci®c lgGs and tested their capability to neutralize apoptosis induced by cross-linked and non-cross-linked sTRAIL. While bivalent TRAIL-R1/-R2-speci®c lgGs showed a profound apoptotic eect, the monovalent Fab preparations derived thereof have completely lost their apoptotic potential (Figure 1a,b) . Jurkat cells express no detectable amounts of TRAIL-R1 and are exclusively killed by TRAIL-R2-speci®c lgG or cross-linked sTRAIL (MuÈ hlenbeck et al., 2000; Schneider et al., 1997) . Apoptosis induced by cross-linked sTRAIL in Jurkat cells was completely prevented by pretreatment with increasing amounts of TRAIL-R2-speci®c Fabs, whereas even the highest concentrations of TRAIL-R1-speci®c Fabs failed to confer protection (Figure 1c ). HeLa cells express and signal apoptosis via both death domain-containing TRAIL receptors and are killed by cross-linked and non-cross-linked sTRAIL (MuÈ hlenbeck et al., 2000) . Apoptosis induced by non-crosslinked sTRAIL was completely prevented by pretreatment with increasing amounts of TRAIL-R1-speci®c Fabs, whereas even the highest concentration of TRAIL-R2-speci®c Fabs had no protective eect (Figure 1d ,e). These data indicated that sTRAIL induced cell death in HeLa cells exclusively via TRAIL-R1. In contrast, to protect HeLa cells from the apoptotic eects of cross-linked sTRAIL, pretreatment with a combination of TRAIL-R1-and TRAIL-R2-speci®c Fabs was necessary (Figure 1f ). Similar data were also obtained for HepG2 and KB cells which Oncogene (2001) 20, 4101 ± 4106 can also be killed by cross-linked and non-cross-linked sTRAIL (data not shown). Taken together these neutralization experiments clearly demonstrate that TRAIL-R1 signals apoptosis upon triggering by crosslinked and non-cross-linked sTRAIL, whereas TRAIL-R2 signals only in response to cross-linked TRAIL.
Based on the above ®ndings, we analysed the impact of our anti-TRAIL-receptor Fabs on the signaling and TRAIL-R2-(b) speci®c rabbit antisera (®lled symbols), raised against TRAIL-R1-Fc and TRAIL-R2-Fc by standard techniques, have lost their apoptotic potential HeLa cells were incubated overnight with the indicated concentrations of the various reagents in the presence of cycloheximide (2.5 mg/ml). Next day cell viability was determined with crystal violet staining (c) TRAIL-R2-Fab (®lled symbols) but not TRAIL-R1-Fab (open symbols) inhibits apoptosis induced by cross-linked sTRAIL on Jurkat cells. Cells were preincubated with the indicated concentration of TRAIL-receptor Fabs and subsequently apoptosis was induced with 200 ng/ml of a¯ag-tagged sTRAIL cross-linked with¯ag-speci®c antibody M2 (1 mg/ml). After overnight incubation cell viability was determined using the MTT method. (d) TRAIL-R1-Fab (open symbols), but not TRAIL-R2-Fab (®lled symbol), inhibits apoptosis induced by sTRAIL on HeLa cells. Cells were preincubated with the indicated concentration of TRAIL-receptor Fabs and subsequently apoptosis was induced with 200 ng/ml of sTRAIL in the presence of CHX (2.5 mg/ml). After overnight incubation cell viability was determined by crystal violet staining. (e,f) HeLa cells were preincubated (1 h 378C) with TRAIL-R1-Fab (50 mg/ ml), TRAIL-R2-Fab (50 mg/ml) or a mixture of them and subsequently challenged for TRAIL-induced apoptosis by adding noncross-linked (e) or cross-linked (f) sTRAIL (100 ng/ml). Cell viability was determined by crystal violet staining (Mariani and Krammer, 1998a,b; Kayagaki et al., 1999; Grith et al., 1999; Fanger et al., 1999) . In addition, in the supernatants of some transformed human T and B cell lines, a soluble TRAIL molecule Cr-labeled Jurkat (c) and HeLa (d) target cells were preincubated with TRAIL-R1-Fab (50 mg/ml), TRAIL-R2-Fab (50 mg/ml) or a mixture of them for 1 h. Subsequently, these target cells were incubated for 16 h at an E/T ratio of three with HEK293 cells 2 days post transient transfection with TRAIL-wt (open bars), TRAIL D(89 ± 106) (®lled bars) and vector control (hatched bars). (e) Supernatants of the HEK293 transfectants used above were concentrated 15-fold and assayed for cytotoxic activity. For this purpose, HeLa cells were incubated with the various SNs for 8 h in the presence of CHX (2.5 mg/ml) and ®nally stained with crystal violet. SNs were tested after centrifugation at 5000 g for 5 min (open bars) and after centrifugation at 100 000 g for 1 h (®lled bars). In all coculture experiments (a ± d), HeLa cells were preincubated for 3 h with CHX (2.5 mg/ml). Cocultures of HeLa cells and transiently transfected HEK293 cells were supplemented with CHX (2.5 mg/ml). Data shown are the mean+s.d of quadruplicate determinations from one representative of at least three independent experiments for each group (a ± e) Oncogene Differential bioactivity of sTRAIL and memTRAIL H Wajant et al Cr release assay was not sucient to exert a signi®cant cytotoxic eect. Thus, memTRAIL signals via TRAIL-R1 and TRAIL-R2, whereas sTRAIL predominantly, if not exclusively, signals via TRAIL-R1.
Facing the dierential receptor usage of sTRAIL and memTRAIL, we wondered whether arti®cial immobilization of sTRAIL on a cell surface could confer to this molecule the capability to eciently activate TRAIL-R2. For this purpose we generated a fusion protein consisting of sTRAIL and MBOS4, a recombinant antibody derivative recognizing the tumor stroma marker ®broblast activation protein (FAP) (Garin-Chesa et al., 1990) . The MBOS4-TRAIL fusion protein (Figure 3a ) was transiently expressed in COS cells and analysed for speci®c binding and bioactivity on FAP-positive and FAP-negative human HT1080 ®brosarcoma cells. Indirect immuno¯uorescence FACS analyses with TRAIL speci®c monoclonal antibodies revealed a strong speci®c binding of the fusion protein to FAP expressing transfectants, and only a barely detectable signal on FAP negative control cells ( Figure  3b ). MBOS4-TRAIL binding could be speci®cally blocked by the murine parental antibody of MBOS4, cF19, indicating predominant binding of the fusion protein via the antibody moiety to FAP rather than via the TRAIL domain and TRAIL-R (Figure 3b) . Analysis of the dose dependency of MBOS4-TRAILinduced apoptosis revealed an approximately 30 times higher sensitivity of the FAP-expressing cells compared to the control (Figure 3c ). More importantly, pretreatment of HT1080-FAP with cF19 reduced the sensitivity of the FAP transfectants towards MBOS4-TRAIL to the level of the FAP negative control cells (Figure 3c ), indicating that the increased sensitivity of the HT1080-FAP cells is not caused by clonal variability. Cotreatment of HT1080-FAP with sTRAIL or aggregated sTRAIL and cF19 resulted in no enhancement of cytotoxicity (Figure 3d ,e), ruling out a contribution of a potential, though presently unknown, antibodyinduced FAP signal pathway and its cooperation with TRAIL-induced signals. Moreover, neutralization experiments with TRAIL-receptor speci®c Fabs clearly showed dominant TRAIL-R2-dependent cell death on FAP-positive cells when low concentrations of MBOS4-TRAIL were used, i.e. under conditions, where the FAP-negative parental cells are not or only modestly sensitive against MBOS4-TRAIL (Figure 3f ). In contrast, higher concentrations of MBOS4-TRAIL killed HT1080 cells independent of FAP expression mainly via TRAIL-R1 (data not shown). Moreover, Jurkat cells, which do not express TRAIL-R1, are resistant against MBOS4-TRAIL, whereas TRAIL-R1-sensitive HeLa cells were readily killed by MBOS4-TRAIL (Figure 3g) . Hence, MBOS4-TRAIL is not dierent from other soluble, non-aggregated TRAIL derivatives with respect to signaling cell death via TRAIL-R1, yet it has, in addition, acquired the capability to activate TRAIL-R2 upon immobilization on FAP expressing cells via its MBOS4-domain.
In contrast to TNF and agonistic Fas antibodies, which have only a very limited or no clinical applicability at all due to potentially live threatening systemic side eects, TRAIL has been regarded as an ideal candidate cytokine for cancer therapy because of its high apoptotic activity on a variety of tumor cells with apparently no activity on most nontransformed TRAIL sucient to induce almost complete cell death (80 ± 100%) in clone 33, but only modest cytotoxic eects on the parental HT1080 cell line. After additional 8 h, cells were assayed for cell viability. (g) Jurkat-(open bars) and HeLa cells (®lled bars) were challenged with the indicated concentrations of MBOS4-TRAIL overnight and assayed for viability by crystal violet staining (HeLa) or MTT cells. In support of this, preclinical studies with mice and cynomolgus monkeys revealed no evidence for tissue toxicity or systemic harmful eects upon administration of recombinant soluble TRAIL Ashkenazi et al., 1999; Walczak et al., 1999) . These promising clinical perspectives have recently been seriously challenged by two independent studies reporting that TRAIL exerts a strong apoptotic activity on primary human hepatocytes in vitro (Jo et al., 2000) as well as in human brain (Nitsch et al., 2000) . Although the molecular mechanisms of the TRAIL-induced cytotoxicity observed in these two studies have not been resolved and the speci®c composition of the recombinant TRAIL preparations used may dier from those tested in other models, the data nevertheless provide compelling evidence for the principle sensitivity of normal human tissues, at least hepatocytes and brain cells, towards the apoptotic action of TRAIL. Accordingly, as for other proapoptotic cytokines, it appears that new safety measures for the clinical application of TRAIL have to be considered alike.
The antibody-mediated targeting and activation of TRAIL shown here may provide a useful approach for several reasons. First, antibody-mediated targeting to the tumor should reduce the risk of eects on normal tissues. Second, due to the dierential activation capacity for TRAIL-R2 of sTRAIL and the antibody-TRAIL fusion protein and thereby coactivation of both death domain-containing TRAIL receptors by the latter, an enhancement of the cytotoxic potential at the relevant target site can be achieved. This should in turn allow a dose reduction, thereby further minimizing the risk of unwanted actions on non-targeted tissues. Third, by exchanging the antibody moiety of the fusion protein, highly selective reagents can be constructed with individual and prede®ned targeting functions. Finally, we envisage that the principle of surface antigen-directed receptor activation by an otherwise inactive or less active soluble ligand should likewise be applicable for other ligands of the TNF family, e.g. FasL or TNF, the latter with respect to TNF-R2 activation. Antigen-selective conferment of bioactivity may represent a novel means of generating cytokines devoid of systemic action and thus appear suitable for a safe clinical application.
